# Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

> **NCT07379268** · — · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 224 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **OTHER:** Organoid culture

## Key facts

- **NCT ID:** NCT07379268
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07379268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07379268, "Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07379268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*